Metrosa (Metronidazole)

Metronidazole enters anaerobic microbial cells and is reduced to reactive nitro‑radical anions. These metabolites bind to DNA, causing strand breakage and blocking nucleic acid synthesis, which leads to microbial cell death. The drug also has anti‑inflammatory properties that help calm skin inflammation.

The exact dosage and frequency of Metrosa are determined by the prescribing clinician based on the severity of the skin condition, the area to be treated and patient‑specific factors. No standard dose is provided here; the prescriber will set the appropriate regimen.

Safety data for metronidazole in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks before prescribing to pregnant or nursing women, and discuss any concerns with the patient.

To request Metrosa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metrosa (metronidazole) belongs to the nitroimidazole class and offers both antimicrobial and anti‑inflammatory effects, which differ from retinoids or azelaic acid that act primarily on keratinocyte turnover. It is often chosen when bacterial involvement or inflammation is prominent, and it may be used in combination with other agents for synergistic benefit.

Metrosa should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct light to maintain stability and potency.

Metrosa is a topical preparation intended for cutaneous use. Apply a thin layer to the affected skin area as directed by the prescriber, typically once or twice daily, and wash hands after application unless treating the hands themselves.

Serious adverse reactions include severe allergic responses such as anaphylaxis, peripheral neuropathy, seizures, hepatotoxicity and blood dyscrasias. Patients should seek immediate medical attention if they experience symptoms like rash, swelling, numbness, jaundice or unexplained bruising.

Metrosa is contraindicated in individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is also advised for patients with severe hepatic impairment, those who consume alcohol heavily, and pregnant or lactating women unless the benefits clearly outweigh the risks.